



# GLAND PHARMA LIMITED

October 18, 2024

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex Bandra  
(East), Mumbai - 400 051  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

## **Sub: Appointment of Chief Executive Officer**

In compliance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Shyamakant Giri, as the new Chief Executive Officer (CEO) of the Company. He is expected to join the Company with effect from January 15, 2025. Mr. Srinivas Sadu will continue to be the Executive Chairman of the Company and support the Company's next phase of growth.

The details, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are given in **Annexure-A**, which is enclosed herewith.

This is for your information and records.

**Yours truly,**  
**For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi**  
**Company Secretary and Compliance Officer**

**Encl:** Annexure A

**Annexure A**

**Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

**Details of Mr. Shyamakant Giri**

<b>Sl. No</b>	<b>Particulars</b>	<b>Remarks</b>
1	Reason for change	Appointment of Mr. Shyamakant Giri, as the Chief Executive Officer of the Company with effect from January 15, 2025.
2	Date of Change	15.01.2025
3	Brief profile	<p>Mr. Shyamakant Giri is a business leader with over 25 years of strategic and operating experience in pharmaceuticals, devices, diagnostics and healthcare services in leading Indian and multinational organizations across Asia, Africa, MENA &amp; LATAM markets.</p> <p>He possesses rich experience in creating new ventures and improving existing businesses, developing leaders, identifying opportunities for value creation, and executing with discipline. His specialties include Business Development, Operations, Strategy, Product Marketing, start-ups, and turnarounds.</p> <p>Mr. Giri is currently the President (India Business &amp; Emerging Markets) of Amneal Pharmaceuticals, responsible for the commercial expansion and growth in India and Rest of the World markets.</p> <p>Previously, Mr. Giri was associated with Rivaara Labs as the Chief Executive Officer. Earlier, Mr. Giri was associated in various roles with Abbott India, AbbVie (India Region) and Abbott Diagnostics for almost eighteen years (2002-2020). Mr. Giri started his professional career with Wockhardt Ltd. and was associated during the period 1999-2002.</p> <p>Mr. Giri has done his Master's in Marketing Management from Jamnalal Bajaj Institute of Management Studies and also holds a Master's degree</p>

		in Science (Organic Chemistry) from Mumbai University. He completed his Executive Programme from INSEAD, Singapore and Executive Programme in Hospital Management from Indian Institute of Management, Ahmedabad.
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable

**Details of Mr. Srinivas Sadu**

SI. No	Particulars	Remarks
1	Reason for change	Consequent to appointment of new CEO of the Company, Mr. Srinivas Sadu shall continue to be the Executive Chairman of the Company.
2	Date of Change	15.01.2025
3	Brief profile	Not Applicable as Mr. Srinivas Sadu has been a Director on the Board since April 25, 2019.
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Mr. Srinivas Sadu is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.